Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Núria Padullés Zamora"'
Autor:
Alejandro Santiago Pérez, Santos Esteban Casado, Miriam Álvarez Payero, Ángel Escolano Escolano Pueyo, Ángel Guillermo Arévalo Bernabé, Núria Padullés Zamora, Pilar Diaz Ruiz, Ana María López González
Publikováno v:
Farmacia Hospitalaria.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::faf4f8a457b70ee7c69a521214d9a732
https://doi.org/10.1016/j.farma.2023.03.009
https://doi.org/10.1016/j.farma.2023.03.009
Autor:
Clara, Ribera-Puig, Pol, Clèries-Rovira, Miriam, Casellas-Gibert, Jordi, Guardiola-Capón, Francisco, Rodríguez-Moranta, Lorena, Rodríguez-Alonso, Alexandra, Ruiz-Cerulla, Fran, Morandeira-Rego, Eugènia, Santacana-Juncosa, Núria, Padullés-Zamora
Publikováno v:
El Farmacéutico Hospitales; may2023, Vol. 225, p37-48, 12p
Autor:
Lorena Rodríguez-Alonso, Francisco Rodríguez-Moranta, Jordi Bas Minguet, Eugènia Santacana Juncosa, Jordi Guardiola, Francisco Morandeira Rego, Helena Colom Codina, Núria Padullés Zamora, Ariadna Padullés Zamora, Katja Serra Nilsson
Publikováno v:
British Journal of Clinical Pharmacology. 87:494-505
Therapeutic drug monitoring of infliximab can guide clinical decisions in patients with loss of response and in those who can benefit from a de-intensification. The aim of this study was to determine the impact of therapeutic drug monitoring combined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d43f6d2a02aeb40abf0e5d95605368d5
https://doi.org/10.1111/bcp.14410
https://doi.org/10.1111/bcp.14410
Autor:
Eugènia Santacana-Juncosa, Ariadna Padullés-Zamora, Helena Colom-Codina, Lorena Rodríguez-Alonso, Jordi Guardiola-Capo, Jordi Bas-Minguet, Núria Padullés-Zamora
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 108, Iss 2, Pp 104-105 (2016)
Externí odkaz:
https://doaj.org/article/a75336667dee4c08ab37f85daa7c083d
Autor:
Orlando Acosta Fernández, Núria Padullés Zamora, Jose Manuel Palma López, Jordi Dorca Sargatal, Agustín Medina Gonzálvez, Jaume Bordas Martinez, Ramón José Jódar Masanés, Laura Pérez Martín, Guadalupe Bermudo Peloche, Guillermo Suarez-Cuartin, Lurdes Planas-Cerezales, Maria Molina Molina, Vanesa Vicens Zygmunt, Ana Belén Llanos-González, Sara García Gil
Publikováno v:
Idiopathic interstitial pneumonias.
Introduction and Aim: Pirfenidone and nintedanib are anti-fibrotic approved treatments for idiopathic pulmonary fibrosis (IPF). Its efficacy and safety in other fibrotic interstitial lung diseases (ILD) is under study in clinical trials. The aim was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bdd32acc62c9a6c20ff1e55e883a372
https://doi.org/10.1183/13993003.congress-2019.pa1731
https://doi.org/10.1183/13993003.congress-2019.pa1731
Autor:
Beatriz Candás-Estébanez, Pedro Alía-Ramos, Núria Padullés-Zamora, Cristina Ruiz-Iruela, Ariadna Padró-Miquel, Daniel Podzamczer-Palter, Arnald Alonso-Pastor
Publikováno v:
Pharmacogenetics and Genomics. 26:390-396
INTRODUCTION Most of the cost-effectiveness analyses are based on estimations to make decisions on the future implementation of a test. However, the model should be verified with real data to prove that previous estimations have been successfully ful
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a94f95a557bbc90ff5c4b9fd143b8870
https://doi.org/10.1097/fpc.0000000000000229
https://doi.org/10.1097/fpc.0000000000000229
Autor:
Javier, Milara, Maria, Outeda-Macias, M Dolores, Aumente-Rubio, Patricio, Más-Serrano, Azucena, Aldaz, M Victoria, Calvo, M Sergia, García-Simón, Marisa, Martin-Barbero, Núria, Padullés-Zamora, Juan Antonio, Schoenenberger, Marianne, Saavedra-Aldrich, Enrique, Tévar-Alfonso, Ana, Saval, Alfonso, Pastor-Clerigues, Marta, García, Luis, Margusino-Framiñan, Jose Luis, Montero-Alvarez, Esperanza, Merino, Jose Ignacio, Herrero, Mónica, Beunza, Pablo, Conesa-Zamora, Alvaro, Gimenez-Manzorro, Dolors, Comas-Sugrañes, Manuel, Cano-Marron, Elena, Jiménez-Mutiloa, Pilar, Díaz-Ruíz, Julio, Cortijo
Publikováno v:
Farmacia Hospitalaria, Vol 39, Iss 1, Pp 29-43 (2015)
Dual PEGylated interferon-α (PEG-IFN) and ribavirin therapy has been the main hepatitis C virus (HCV) treatment of the last decade. Current direct-acting antiviral agents have improved the outcome of therapy but also have increased the cost and mana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::3a3594e1d51a1c103663f63fcf45bc96
http://www.aulamedica.es/fh/pdf/8547.pdf
http://www.aulamedica.es/fh/pdf/8547.pdf
Publikováno v:
Farmacia Hospitalaria. 34:312-314
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00cc280fffcc609053ac3859ee557b93
https://doi.org/10.1016/j.farma.2009.12.011
https://doi.org/10.1016/j.farma.2009.12.011
Autor:
Eugènia, Santacana-Juncosa, Núria, Padullés-Zamora, Ariadna, Padullés-Zamora, Dolors, Comas-Sugrañes, Lorena, Santulario-Verdú, Núria, Sanmartí-Martínez, Alberto, Martínez-Castelao
Publikováno v:
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 34(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f9a4450ff4eaf2f023e476c37e23b014
https://pubmed.ncbi.nlm.nih.gov/24658202
https://pubmed.ncbi.nlm.nih.gov/24658202
Autor:
Núria, Padullés Zamora, Dolors, Comas Sugrañes, Nadia, Méndez Cabaleiro, Anna, Figueras Suriol, Ramon, Jodar Masanes
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 37(5)
To assess the efficacy and safety profile of omalizumab treatment. The conditions under which omalizumab was prescribed agreed with those in Xolair® drug information: age12 years old, severe uncontrolled asthma, FEV180%, IgE 30-700 UI/ml and positiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1501a89867203cff055513308550ddf5
https://pubmed.ncbi.nlm.nih.gov/24128103
https://pubmed.ncbi.nlm.nih.gov/24128103